stonks4u
Sign up free
RVMD logo

RVMD Revolution Medicines, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$203.71
+1.71 (+0.85%)

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorect…

Market Cap: $43.31Bwww.revmed.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

70
70
Aug 10Aug 10

Quote

Day Range
$198.89 – $204.00
52-Week Range
$35.42 – $208.76
Volume
$771.8K
Market Cap
$43.31B
50-Day Avg
$180.67
200-Day Avg
$122.81
Prev Close
$202.00
Open
$201.50

Valuation & Ratios

P/E Ratio
-13.39
EPS
$-5.95
P/B Ratio
9.28
P/S Ratio
0.00
Debt/Equity
0.10
Current Ratio
7.14
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-69.3%
Return on Assets
-48.0%
FCF Yield
-6.0%
EV/EBITDA
-13.68

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-1.13B$-5.95
2024$0.00$-600.09M$-3.58
2023$11.58M$-436.37M$-3.86
2022$35.38M$-248.71M$-3.08
2021$29.39M$-187.09M$-2.47

Social Signal Score

20
5d
—
30d
20
1 mentions
—
60d
20
1 mentions
—
90d
20
1 mentions
—
news: 1

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $-2.45 per share

0of 7 quarters beat consensus

Typical surprise -17.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 5$-3.06 vs $-2.04miss
  • Wed, May 6$-2.29 vs $-1.84miss
  • Wed, Feb 25$-1.86 vs $-1.58miss
  • Wed, Nov 5$-1.61 vs $-1.42miss
  • Wed, Aug 6$-1.31 vs $-0.94miss
  • Wed, May 7$-1.13 vs $-1.12miss

Estimates and results for RVMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

RVMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsbusinesswire.com·5d ago·Negative

    BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinica

    View source ↗